A primer-probe combination, method and kit for detecting Cryptococcus neoformans

By designing primer probe combinations and fluorescence quantitative PCR technology for Cryptococcal neoplasms, the problems of low sensitivity and time-consuming existing Cryptococcal detection methods are solved, and the rapid and accurate detection of Cryptococcal neoplasms is achieved, supporting early diagnosis and treatment.

CN117165714BActive Publication Date: 2024-11-19BEIJING SHIJITAN HOSPITAL CAPITAL MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311312452.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-11
Publication Date
2024-11-19
Estimated Expiration
2043-10-11

AI Technical Summary

Technical Problem

The existing Cryptococcus detection methods are less sensitive, take a long time, and cannot distinguish the types of Cryptococcus, resulting in difficulty in early detection and typing of Cryptococcus neoformans and affecting the treatment effect.

Method used

A primer probe combination for specific gene fragments of Cryptococcal neoformans was designed. Through polymerase chain reaction PCR technology, combined with fluorescence quantitative detection, it can quickly and accurately identify and detect Cryptococcal neoformans.

Benefits of technology

It improves the efficiency and accuracy of Cryptococcal neoplasm detection, can achieve clinically advanced diagnosis and treatment plans, reduce drug abuse, and has simple operation and short detection time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117165714B_ABST
    Figure CN117165714B_ABST
Patent Text Reader

Abstract

The present application relates to a primer-probe combination, method and kit for detecting Cryptococcus neoformans. In the primer-probe combination, the primers include a forward primer and a reverse primer, the nucleotide sequence of the forward primer is shown in Seq ID No.1, the nucleotide sequence of the reverse primer is shown in Seq ID No.2; the nucleotide sequence of the probe is shown in Seq ID No.3. The primer-probe combination provided in the present application can accurately and efficiently detect Cryptococcus neoformans, and can also identify the type of Cryptococcus while detecting Cryptococcus, helping clinicians to quickly and accurately diagnose diseases caused by Cryptococcus neoformans and reduce drug abuse.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the technical field of fungal pathogen detection, and specifically relates to a primer-probe combination, method and kit for detecting Cryptococcus neoformans. Background Art

[0002] Cryptococcus is a type of pathogenic fungus that endangers human health. Different types of cryptococcus have obvious differences in epidemiology and clinical pathogenicity. Among them, Cryptococcus neoformans is a type of pathogenic cryptococcus that mainly infects immunosuppressed people, causing more than 600,000 deaths each year. Cryptococcus neoformans usually enters the human lungs through the respiratory system, spreads to different organs through the blood, and eventually crosses the blood-brain barrier into the brain to cause meningitis. Cryptococcus neoformans infection is usually an invisible infection, which is not easy to detect in the early clinical stage and is easy to misdiagnose. Therefore, early detection and typing of Cryptococcus neoformans are crucial for the treatment of cryptococcosis.

[0003] Although existing cryptococcal detection methods such as ink staining and culture identification can detect cryptococci, they have low sensitivity, are time-consuming, and cannot detect the type of cryptococci. Therefore, how to quickly and accurately detect Cryptococcus neoformans has become a technical problem that needs to be solved urgently. Summary of the invention

[0004] The present application provides a primer-probe combination, method, kit for detecting Cryptococcus neoformans, and the application of the primer-probe combination in detecting Cryptococcus neoformans. By designing a corresponding primer-probe combination for a specific gene fragment of Cryptococcus neoformans, Cryptococcus neoformans can be accurately detected, helping to improve the detection efficiency and accuracy of Cryptococcus neoformans.

[0005] In the first aspect, the present application provides a primer-probe combination for Cryptococcus neoformans, wherein the primers include a forward primer and a reverse primer, the nucleotide sequence of the forward primer is shown in Seq ID No.1, and the nucleotide sequence of the reverse primer is shown in Seq ID No.2; the nucleotide sequence of the probe is shown in Seq ID No.3.

[0006] In some embodiments, the primer is used to recognize the nucleotide sequence shown in Seq ID No.4 in the Cryptococcus neoformans.

[0007] In some embodiments, the 5' end of the probe is connected to a fluorescent reporter group, and the 3' end of the probe is connected to a fluorescent quencher group.

[0008] In some embodiments, the probe is:

[0009] FAM-GTGAGTTCCCCGTCTTTTTC-BHQ1.

[0010] In a second aspect, a method for detecting Cryptococcus neoformans is provided, the method comprising: obtaining a template DNA of a sample to be tested; amplifying the template DNA by polymerase chain reaction (PCR) to obtain an amplification result, wherein the PCR reactants include the primer-probe combination in any embodiment of the first aspect; and judging whether the detection result of Cryptococcus neoformans in the sample to be tested is positive or negative based on the amplification result.

[0011] In some embodiments, the sample to be tested includes blood, body fluid and / or lung tissue.

[0012] In some embodiments, judging whether the detection result of Cryptococcus neoformans in the sample to be tested is positive or negative according to the amplification result includes: when there is a logarithmic increase in fluorescence in the amplification result and the cycle threshold Ct is less than or equal to 30.0, judging that the detection result of Cryptococcus neoformans in the sample to be tested is positive; or when there is no logarithmic increase in fluorescence in the amplification result and the cycle threshold Ct is greater than 30.0, judging that the detection result of Cryptococcus neoformans in the sample to be tested is negative; or when there is a fluorescence increase in the amplification result and the cycle threshold Ct is greater than 30.0, judging that the detection result of Cryptococcus neoformans is negative.

[0013] In a third aspect, an embodiment of the present application provides a kit for detecting Cryptococcus neoformans, wherein the kit comprises the primer-probe combination of any embodiment of the present application.

[0014] In some embodiments, the kit further comprises: a buffer, a template DNA, a DNA polymerase and / or deoxynucleoside triphosphate dNTPs.

[0015] In a fourth aspect, the present application also provides an application of the primer-probe combination described in any embodiment of the present application in detecting Cryptococcus neoformans. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 It is a schematic flow chart of a method for detecting Cryptococcus neoformans in an embodiment of the present application.

[0017] Figure 2 It is a specific amplification curve diagram of Cryptococcus neoformans in the example of the present application. DETAILED DESCRIPTION

[0018] The technical solution of the present application is further introduced below in conjunction with specific embodiments.

[0019] "Scope" disclosed in the present application is limited in the form of lower limit and upper limit, and a given range is limited by selecting a lower limit and an upper limit, and the selected lower limit and upper limit define the boundary of a special range. The scope limited in this way can be including end values ​​or not including end values, and can be arbitrarily combined, that is, any lower limit can be combined with any upper limit to form a scope. For example, if the scope of 60-120 and 80-110 is listed for a specific parameter, it is understood that the scope of 60-110 and 80-120 is also expected. In addition, if the minimum range values ​​1 and 2 are listed, and if the maximum range values ​​3, 4 and 5 are listed, the following scope can be all expected: 1-3, 1-4, 1-5, 2-3, 2-4 and 2-5. In the present application, unless otherwise specified, the numerical range "ab" represents the abbreviation of any real number combination between a and b, wherein a and b are real numbers. For example, the numerical range "0-5" means that all real numbers between "0-5" are listed in this document, and "0-5" is just an abbreviation of these numerical combinations. In addition, when a parameter is expressed as an integer ≥ 2, it is equivalent to disclosing that the parameter is, for example, an integer of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, etc.

[0020] In the description of the present application, the terms “first”, “second”, “third”, etc. are used for descriptive purposes only and should not be understood as indicating or implying relative importance.

[0021] If there is no special explanation, the "include" and "comprising" mentioned in this application are open-ended or closed-ended. For example, the "include" and "comprising" may mean that other components not listed may also be included or only the listed components may be included or only the listed components may be included.

[0022] If not specifically stated, in this application, the term "or" is inclusive. For example, the phrase "A or B" means "A, B, or both A and B". More specifically, any of the following conditions satisfies the condition "A or B": A is true (or exists) and B is false (or does not exist); A is false (or does not exist) and B is true (or exists); or both A and B are true (or exist).

[0023] Unless otherwise specified, all embodiments and optional embodiments of the present application can be combined with each other to form a new technical solution.

[0024] Cryptococcus is a type of fungus that can cause cryptococcosis. In fungal taxonomy, it belongs to the subphylum Ascomycota, class Bacillus, and family Cryptococcaceae. Cryptococcosis is a pulmonary or disseminated infectious disease caused by Cryptococcus, mainly causing pneumonia, meningitis, skin or organ infections. There are many species in the genus Cryptococcus, among which the main ones that cause human infection are Cryptococcus neoformans and Cryptococcus gattii.

[0025] Cryptococcus neoformans is the most important human pathogenic fungus in the phylum Basidiomycetes and one of the important fungal pathogens that causes death in immunocompromised people, causing more than 600,000 deaths each year. Cryptococcus neoformans usually enters the host's lungs through the respiratory system, spreads to different organs through the blood, and can eventually cross the blood-brain barrier into the brain to cause meningitis. The mortality / disability rate of meningitis caused by this bacterium is high, and even in countries and regions with developed diagnosis and treatment such as Europe and the United States, the infection mortality rate is still more than 20%. In addition, Cryptococcus neoformans infection in my country is relatively unique, with a tendency to infect people with sound immunity, and has become the main pathogen of infectious encephalitis in some areas, posing a more severe challenge to my country's public health and safety.

[0026] Although existing cryptococcal detection methods such as ink staining and culture identification can detect cryptococci, they have low sensitivity, take a long time to detect, and cannot distinguish the types of cryptococci, which is not conducive to the rapid diagnosis of cryptococcal disease and the formulation of treatment plans in clinical practice.

[0027] In view of this, the present application provides a primer-probe combination for detecting Cryptococcus neoformans. The polymerase chain reaction (PCR) based on the primer-probe combination can accurately and quickly detect Cryptococcus neoformans and determine the type of Cryptococcus while detecting Cryptococcus.

[0028] First, the present application embodiment provides a primer-probe combination for detecting Cryptococcus neoformans.

[0029] The primers include a forward primer and a reverse primer. The nucleotide sequence of the forward primer is shown in Seq ID No.1, the nucleotide sequence of the reverse primer is shown in Seq ID No.2, and the nucleotide sequence of the probe is shown in Seq ID No.3.

[0030] Specifically, the inventors used bioinformatics methods to compare the entire genomes of bacteria such as Cryptococcus neoformans, Cryptococcus gattii, Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, and Candida albicans, not limited to a single coding gene, but to find differential sites at the level of the entire genome, thereby designing primers with nucleotide sequences as shown in Seq ID No. 1 and Seq ID No. 2. The primers can specifically recognize the nucleotide sequence shown in Seq ID No. 4 that only Cryptococcus neoformans has, and the primers are used to efficiently and accurately detect Cryptococcus neoformans.

[0031] Wherein, the nucleotide sequence of the forward primer is specifically:

[0032] CCCGTCCCAGTGGACTTTAC.

[0033] The nucleotide sequence of the reverse primer is specifically:

[0034] TTGTAGCCCGGGACAAAGAC.

[0035] The primer is used to recognize the nucleotide sequence in Cryptococcus neoformans as shown in Seq ID No. 4. In other words, the primer designed for Cryptococcus neoformans can specifically recognize the nucleotide sequence in Cryptococcus neoformans as shown in Seq ID No. 4.

[0036] Optionally, the 5' end of the probe is connected to a fluorescent reporter group, and the 3' end of the probe is connected to a fluorescent quencher group.

[0037] Among them, the fluorescent reporter groups include but are not limited to 6-carboxyfluorescein (FAM), tetrachloro-6-carboxyfluorescein (TET), 2,7-dimethyl-4,5-dichloro-6-carboxyfluorescein (JOE), hexachloro-6-methylfluorescein (HEX), anthocyanin fluorescent dye CY3, 6-carboxy-tetramethylrhodamine (TAMRA). The fluorescent quencher groups include but are not limited to 6-carboxy-tetramethylrhodamine (TAMRA), 4-(4-oxanylaminophenylazo)benzoic acid (DABCYL) or black hole quenchers BHQ1, BHQ2, BHQ3.

[0038] For example, the 5' end of the probe is connected to a FAM group, and the 3' end of the probe is connected to a BHQ1 group. That is, the probe is:

[0039] FAM-GTGAGTTCCCCGTCTTTTTC-BHQ1.

[0040] The above primer-probe combination has the obvious advantages of high sensitivity and strong specificity in detecting and identifying Cryptococcus neoformans. While detecting Cryptococcus, it can also determine whether the Cryptococcus is Cryptococcus neoformans, thereby helping in the early diagnosis of cryptococcal disease in clinical practice and the formulation of treatment plans, buying precious time for the treatment of the disease.

[0041] The embodiment of the present application also provides a method 100 for detecting Cryptococcus neoformans.

[0042] Figure 1 1 is a schematic flow chart of a method 100 for detecting Cryptococcus neoformans according to an embodiment of the present application. Figure 1 As shown, the method 100 includes:

[0043] S101, obtaining template DNA of the sample to be tested.

[0044] S102, amplifying the template DNA of the sample to be tested by polymerase chain reaction (PCR) to obtain an amplification result, wherein the PCR reactants include the primer-probe combination in any embodiment of the present application.

[0045] S103, judging whether the detection result of Cryptococcus neoformans in the sample to be tested is positive or negative according to the amplification result.

[0046] Specifically, the primer-probe combination provided in the present application can effectively detect whether Cryptococcus neoformans exists in the sample to be tested by fluorescent quantitative PCR, for example, by performing fluorescent quantitative PCR detection by TaqMan probe method.

[0047] Optionally, the sample to be tested includes blood, body fluid, and / or lung tissue.

[0048] Optionally, in S103, judging whether Cryptococcus neoformans in the sample to be tested is positive or negative according to the amplification result includes:

[0049] In the amplification result, when the fluorescence logarithm of the fluorescent reporter group increases and the cycle threshold Ct is less than or equal to 30.0, the detection result of Cryptococcus neoformans in the sample to be tested is judged to be positive.

[0050] In the amplification result, when the fluorescence reporter group has no logarithmic fluorescence growth or the first fluorescence reporter group has a logarithmic fluorescence growth but the cycle threshold Ct is greater than 30.0, the detection result of Cryptococcus neoformans in the sample to be tested is judged to be negative.

[0051] The embodiments of the present application also provide a kit for detecting Cryptococcus neoformans, wherein the kit comprises the primer-probe combination in any embodiment of the present application.

[0052] Optionally, the kit further comprises: a buffer, a template DNA, a DNA polymerase and / or deoxynucleotide triphosphate dNTP.

[0053] Optionally, the kit further comprises MgCl2.

[0054] The kit provided in the embodiment of the present application has the above primer-probe combination, which can specifically identify the nucleotide sequence shown in Seq ID No. 4 in Cryptococcus neoformans, thereby accurately and quickly detecting Cryptococcus neoformans. The method 100 has the advantages of simple operation, short detection time, and strong adaptability, which can help achieve rapid and accurate clinical diagnosis and win precious time for disease treatment.

[0055] In addition, an embodiment of the present application also provides a use of a primer-probe combination as in any of the above embodiments in detecting Cryptococcus neoformans.

[0056] Next, the specific steps of the detection method 100 provided in the present application are further introduced. It should be understood that the following examples are only for illustrating the implementation of the identification method of the present application, wherein the specific reagent dosage or instrument usage can be adjusted as needed, and does not constitute a limitation on the examples of the present application.

[0057] Example 1: Extraction of template DNA

[0058] 1. Test materials: samples to be tested

[0059] The samples to be tested described in the present application include but are not limited to blood, body fluids or lung tissues.

[0060] 2. Main reagents and instruments

[0061] DNA was extracted using the yeast gene extraction kit from Tiangen Company; the synthesis of primers and probes was completed by Bioengineering Co., Ltd.; DNA polymerase was purchased from Takara Company; and the fluorescent quantitative PCR instrument was purchased from Roche Company.

[0062] 3. Experimental Methods

[0063] DNA was extracted according to the instructions of the DNA extraction kit, and the DNA content in the sample was determined using a spectrophotometer, and the OD260 / OD280 ratio was determined. The sample to be tested provided in this example contained Cryptococcus neoformans and Cryptococcus gattii.

[0064] Example 2: PCR amplification reaction

[0065] 2.1 PCR detection of Cryptococcus neoformans

[0066] 1. Test Materials

[0067] Template DNA. The specific PCR reaction system is shown in Table 1.

[0068] 2. Main reagents and instruments

[0069] Table 1: Real-time fluorescence PCR reaction system (25 μL)

[0070]

[0071] 3. Experimental Methods

[0072] In this example, the PCR amplification reaction was performed using the Prime STAR 2X Mix PCR amplification kit of TAKARA Company. The PCR amplification process can be found in the product instruction manual of the kit.

[0073] In this example, the nucleotide sequence of the forward primer in the reaction system is shown in Seq ID No.1, the nucleotide sequence of the reverse primer is shown in Seq ID No.2, and the nucleotide sequence of the probe is shown in Seq ID No.3.

[0074] In this embodiment, the amplification conditions of the PCR reaction are: 95 o C pre-denaturation for 5 min; 95 o C 10s, 68o C for 60 s and 45 cycles to obtain the amplification results.

[0075] 4. Analyze and judge the amplification results

[0076] Figure 2 This is the amplification curve of Cryptococcus neoformans obtained through the above operation in the example of the present application. Figure 2 In the amplification curve, the ordinate is the relative fluorescence unit (RFU) and the abscissa is the number of amplification cycles.

[0077] like Figure 2 As shown, in the test results of the sample to be tested, Cryptococcus neoformans was specifically amplified, with a corresponding amplification curve, the FAM fluorescence had a logarithmic increase in fluorescence, and Ct≤30.0. However, the Cryptococcus gattii in the parallel experiment was not amplified. Therefore, the detection result of Cryptococcus neoformans in the sample to be tested was positive. This shows that the primer-probe combination has good specificity for Cryptococcus neoformans and can accurately detect Cryptococcus neoformans in the sample to be tested. Moreover, the three amplification curves of Cryptococcus neoformans have almost the same logarithmic increase in fluorescence, indicating that the detection method using this primer-probe combination has good repeatability. In addition, Figure 2 The template DNA concentration was 0.1 ng / μL, and PCR had a good fluorescence logarithmic response, indicating that the detection method using this primer-probe combination has excellent sensitivity.

[0078] Therefore, the primer-probe combination provided in the present application can accurately and efficiently detect Cryptococcus neoformans.

[0079] In summary, the primer-probe combination provided in the present application has good specificity for Cryptococcus neoformans, so that the detection of Cryptococcus neoformans using the primer-probe combination has good repeatability and sensitivity. The use of a kit containing the primer-probe combination to detect Cryptococcus neoformans can meet the clinical needs of rapid and accurate detection of Cryptococcus, and the operation is simple and the results are reliable, which helps physicians to formulate appropriate treatment strategies in the early clinical stage and reduce drug abuse.

[0080] In the description of this specification, the description with reference to the terms "one embodiment", "an implementation", "some embodiments", "illustrative implementation", "example", "specific example", or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the implementation or example are included in at least one implementation or example of the present application. In this specification, the schematic representation of the above terms does not necessarily refer to the same implementation or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more implementations or examples in a suitable manner.

[0081] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present application, rather than to limit it. Although the present application has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present application.

Claims

1. A primer-probe combination for detecting Cryptococcus neoformans, It is characterized in that The primers include a forward primer and a reverse primer, the nucleotide sequence of the forward primer is shown in Seq ID No.1, and the nucleotide sequence of the reverse primer is shown in Seq ID No.2; the nucleotide sequence of the probe is shown in Seq ID No.3; the primers are used to identify the nucleotide sequence shown in Seq ID No.4 in the Cryptococcus neoformans, and the nucleotide sequence shown in Seq ID No.4 is specific to the whole genomes of Cryptococcus gattii, Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli and Candida albicans; the primer-probe combination is used to detect the Cryptococcus neoformans in a sample including the Cryptococcus neoformans and Cryptococcus gattii.

2. The primer-probe combination according to claim 1, It is characterized in that The 5' end of the probe is connected to a fluorescent reporter group, and the 3' end of the probe is connected to a fluorescent quencher group.

3. The primer-probe combination according to claim 2, It is characterized in that The probe is: FAM-GTGAGTTCCCCGTCTTTTTC-BHQ1.

4. A kit for detecting Cryptococcus neoformans, It is characterized in that The kit comprises the primer-probe combination according to any one of claims 1 to 3.

5. The kit according to claim 4, It is characterized in that The kit further comprises: a buffer, a template DNA, a DNA polymerase and / or deoxynucleoside triphosphate dNTP.

6. Use of the primer-probe combination according to any one of claims 1 to 3 in preparing a kit for detecting Cryptococcus neoformans.